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Often regarded as “benign,” Plasmodium vivax infections lay in the shadows of the much more virulent P. falciparum infections.
However, about 1.98 billion people are at risk of both parasites worldwide, stressing the need to understand the epidemiology of
Plasmodium vivax, particularly under the scope of decreasing P. falciparum prevalence and ecological interactions between both
species.Twoepidemiologicalobservationsputthedynamicsofbothspeciesintoperspective:(1)ACTcampaignshavehadagreater
impact onP. falciparum prevalence. (2) Complete clinical immunity is attained at younger ages for P. vivax, under similar infection
rates. We systematically compared two mathematical models of transmission for both Plasmodium species. Simulations suggest
that an ACT therapy combined with a hypnozoite killing drug would eliminate both species. However, P. vivax elimination is
predicted to be unstable. Diﬀerences in age proﬁles of clinical malaria can be explained solely by P. vivax’s ability to relapse, which
accelerates the acquisition of clinical immunity and serves as an immunity boosting mechanism. P. vivax transmission can subsist
in areas of low mosquito abundance and is robust to drug administration initiatives due to relapse, making it an inconvenient and
cumbersome, yet less lethal alternative to P. falciparum.
1.Introduction
Plasmodiumfalciparumhastraditionallybeenthemainfocus
of malaria control programs worldwide, mainly because this
parasite is the major cause of severe morbidity and mortality
intropicalAfrica.However,atatimewhenglobaleradication
is advocated as the ultimate goal of malaria control strategies
worldwide, P. vivax needs to be given much more attention
from researchers, policy makers, and funding agencies. P.
vivax is a major public health challenge in Central and South
America, the Middle East, Central, South, and Southeast
Asia, Oceania, and East Africa, where 2.85 billion people are
currently at risk of infection [1] and as many as 250 million
infections may be due to this species each year [2]. The
emergence of drug-resistant strains and severe (sometimes
fatal) disease challenges the traditional view of vivax malaria
as a benign infection [3].
Although cytoadhesion of P. vivax-infected erythrocytes
to endothelial cells has been recently demonstrated and
might contribute to the pathogenesis of severe vivax malaria
[4], this phenomenon is likely to be much less common than
withP. falciparum infections [5]. Compared to P. falciparum,
P. vivax has a slightly longer incubation period (12 days to
several months) and a similarly phased erythrocytic cycle
(42–48 hours) that yields fewer merozoites per schizont [6].
However, the distinct ability of P. vivax to stay dormant
in host’s liver cells and cause relapses weeks or months
after the primary infection is the most striking diﬀerence
between P. vivax and P. falciparum. Although the molecular
mechanism of relapse remains undisclosed, progression of
theparasitethroughitslifecycleisfairlywelldescribed[5,6].
A proportion of sporozoites remain dormant in the liver, as
hypnozoites,forprolongedperiodsoftimebeforedeveloping
and causing recurrent infection.
The ability to relapse is thought to render P. vivax
resilient to eradication eﬀorts. In fact, in areas where both
species are present, ACT (artemisinin-based combination
therapy) campaigns have had a greater impact on P. falci-
parum than on P. vivax prevalence [7, 8]. We demonstrate2 Journal of Parasitology Research
how this is evident when contemplating elimination scenar-
ios, with P. vivax elimination being extremely diﬃcult to
achieve by mass drug administration.
Immunity to human malaria is largely species speciﬁc.
Epidemiological studies have accumulated evidence that
clinical (antidisease) and antiparasite immunity is attained
at younger ages for P. vivax, when compared to P. falciparum,
under similar infection rates [9–11]. This suggests that
immunity is acquired through diﬀerent mechanisms [12].
We put forward an alternative hypothesis arguing that
diﬀerences between the observed age proﬁles lie in the
characteristic life cycles of both parasites. Explicitly, we
propose that the ability of P. vivax to relapse can accelerate
the piecemeal acquisition of clinical immunity.
2. Methods
Wedevelopedamodelrepresentingthetransmissiondynam-
ics of P. vivax by adding new elements to the foundation
laid by previous work in P. falciparum [13]. We have thus
am o d e ls t r u c t u r ef o rP. vivax transmission, represented
by Figure 1(a), which contains the topology representing
P. falciparum as a submodel (Figure 1(b)). The falciparum
dynamics are retrieved by equating p1 to 1 in the P. vivax
model. Natural history of P. vivax infection is generally
similar to that of P. falciparum, with a few but crucial
idiosyncrasies.
Susceptible individuals (S) are subject to a certain rate
of infection (here represented by the force of infection Λ),
which depends on local environmental and socioeconomic
factors. In P. vivax, after a mosquito infectious bite, an inde-
terminate proportion of the inoculated sporozoites remains
dormant in the liver, whilst the remaining develops into
erythrocyte invading merozoites. The model describing the
transmission dynamics of P. vivax must then include a latent
class, representing those individuals who, after recovering
from infection, keep a remnant of dormant liver forms,
called hypnozoites (subject to reactivation at rate ω) rather
than clearing all parasites while acquiring clinical immunity.
Reactivationisstillarathercrypticprocess,andmostrelapses
seem to result from activation of heterologous hypnozoites
[14], which suggests that genotype-speciﬁc immunity some-
how modulates the occurrence of relapses, much to the
resemblance of how the clinical outcome of a given infection
is determined [15]. Here, parameter p1 accounts for episodes
not followed by a relapse, either because no hypnozoites
were formed or because the remaining hypnozoites do not
reactivate during their lifespan. For illustration purposes,
throughout the paper we keep p1 = 0.25 for P. vivax (and
p1 = 1f o rP. falciparum).
It is generally accepted that the severity of malaria
episodes decreases as the host accumulates exposures to the
parasite. We implement this aspect of malaria immunity by
discretizing the malaria clinical spectrum into two compart-
ments: I1 represents the severe end of the spectrum, and is
labeled “clinical malaria,” while I2 represents the less severe
part and is labeled “asymptomatic malaria”. Naturally, there
is a degree of arbitrariness in this compartmentalization,
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Figure 1: Plasmodium transmission dynamics. (a) Illustration of
the natural history of infection with the P. vivax parasite. The
variables represent a classiﬁcation of the population at any given
age and time into six states: completely susceptible (S); clinical
malaria resulting from an infection in a completely susceptible
individual (I1); recovered with clinical immunity without any
hypnozoites (R); mild or asymptomatic infection resulting from
exposure of recovered individuals (I2); recovered with a certain
degree of clinical immunity, carrying hypnozoites (L1); recovered
with clinical immunity, carrying hypnozoites (L2). Description and
values for the parameters can be found in Table 1.( b )P. falciparum
transmission dynamics. This is a subset of the previous system
which is retrieved by making p1 = 1.
and the results should be interpreted in this context. We
consider that immunologically na¨ ıve individuals will display
clinical symptoms when infected (I1). Although P. vivax
infections are generally not as severe as those caused by P.
falciparum, they are far from benign. Community studies
have revealed that the proportion of P. vivax infections
presenting with fever is similar to the one registered for
P. falciparum [16]. Relapse originates either new clinical
episodes or asymptomatic infections in accordance with
empirical data [17]. The probability of clinical outcome
upon relapse in individuals that kept hypnozoites (L1)f r o m
a previous clinical infection is determined by parameter
p2. Latent individuals carrying hypnozoites are subject to
reinfection at rate Λ, with the resultant infection phenotype
being determined by parameter p2 as well.
Individuals who have just recovered from a clinical
malaria episode are said to have acquired temporary clinical
immunity (R). This means that they do not display clin-
ical symptoms upon reinfection and that, unless they are
challenged again within a given time frame, they will lose
that clinical protection. The same applies to those who have
just recovered from an asymptomatic infection. In fact these
infections are crucial in boosting acquired clinical immunity,
and the interplay between the rate of infection in clinically
immune individuals and the rate of clinical immunity loss
is fulcrum in determining the number of expected clinical
malaria cases during one’s lifespan [18]. As such, thoseJournal of Parasitology Research 3
Table 1: Model parameters.
Parameter Description Value
μ Birth and death rate 0.02years−1
β Transmission coeﬃcient varying
λ Force of infection varying
τ1 Recovery rate from clinical infection 14.12years−1
τ2 Recovery rate from asymptomatic infections 2.23years−1
ω Relapse rate 12years−1
α Rate of loss of clinical immunity 1.07years−1
p1 Proportion of vivax infections which recover with hypnozoites varying
p2 Proportion of relapses which are clinical varying
recovering from an asymptomatic infection are also subject
to loss of immunity at rate α. These include individuals that
either clear all parasite forms and return to R (a proportion
p1) or keep a remnant of hypnozoites and go to the L2 class.
Weconsiderthat,inthelattercase,subsequentinfectionsand
relapse will give rise to asymptomatic malaria.
The described dynamics can be written as the following
system of diﬀerential equations:
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(1)
with boundary conditions at age a = 0: S(t,0) = μ and
Ii(t,0)= Li(t,0)= R(t,0)= 0f o ri = 1,2.
The P. falciparum transmission dynamics are retrieved by
making p1 = 1:
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The force of infection was constructed as an age-
dependent parameter [13]
λ(a) = λ0

1 −ce−ka

. (3)
The function is strictly increasing with age, with a minimum
λ0(1 −r) (at age zero) converging asymptotically to λ0 as age
increases. Parameter k determines how steeply the force of
infection increases with age, and r controls the magnitude
of that increase. A summary measure of transmission is
obtained by integrating the force of infection over age as
Λ =

λ(a)P(a)da,( 4 )
where P(a) = μe−μa is the total population distributed
over age and μ is the birth and death rate. Adopting
standard assumptions, Λ is proportional to the frequency of
infectiousindividuals,theproportionalityconstantbeingthe
transmission coeﬃcient,
β =
Λ
I1 +I2
. (5)
This standard assumption allows us to analyze how the
equilibrium behavior of the system depends on β,w h i c hi s
a critical transmission parameter, representing the sylvatic
portion of the classical Macdonald formulation of the basic
reproduction number for vector-borne diseases [19]. The
basic reproduction number for the P. vivax model presented
here assumes the form
R0 =
β

εp2N1 +τ1εp1N2 +τ2εp1N3 +μ

ε +μ

N4 +τ1εN5

ε2μD1 +εμτ2D2 +τ1αD3 +τ1ε2p1D4 +μ2D5 +μ3D6
,
(6)
where
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
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
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
+ατ2,
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N4 =

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
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
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
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
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
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
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
,
D3 = μ

ε +τ2 − p2ε + p2εp1

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D4 = τ2 − p2τ2 + p2μ+ p2τ2p1,
D5 = (τ1 +ε)(α +τ2)+τ2

α+εp1

+ετ1

2 − p2 − p2p1 +ε2
,
D6 = μ+τ2 +α+τ1 +2 ε.
(7)
Epidemiological changes are often attributed to thresh-
olds in transmission, and these are detected through lon-
gitudinal trends and comparative studies across multiple
communities. Weconsiderthetransmissioncoeﬃcient,β (or
the basic reproduction number, R0)a sac o n t r o lp a r a m e t e r
and describe the signiﬁcance of these indices of transmission
onselectedepidemiologicalvariables.Todoso,wecalculated
the endemic equilibria for systems (1)a n d( 2), without age
dependence.Ageproﬁleswereobtainedbyfollowingacohort
under the pressure of an age-dependent force of infection
deﬁned by (3), for 20 years. The common variables between
systems (1)a n d( 2) have the same boundary conditions. We
used the escalator boxcar train (EBT) technique to simulate
the dynamics in our age-structured population [20].
To assert the beneﬁts of speciﬁc interventions we ﬁrst
simulateourage-structuredmodelinequilibriumconditions
toobtaintheageproﬁleofclinicaldiseaseprevalencewithout
intervention. We use that age proﬁle as the initial condition
for the simulation in which the drug administration trial is
in vigor. The simulated antimalarial treatment consists of
treatingeveryinfectedindividual,regardlessofsymptoms.In
such a setup, asymptomatic malaria is treated as eﬀectively
as clinical malaria, and thus the recovery rate from an
asymptomatic infection, τ2, takes the same value as the
recovery rate from a clinical infection, τ1.
3. Results
The expected prevalence of malaria cases of each Plasmod-
ium species is highly dependent on local environmental
and socioeconomic factors that can be summarized into
some transmission index. In Figures 2(a) and 2(c), infec-
tious proportions are plotted in terms of a transmission
coeﬃcient, β, which encapsulates information on contact
rates and infectivity. Comparing the model outputs for the
P. falciparum (red) and P. vivax (blue) systems, we verify
that, if a signiﬁcant proportion of individuals recovers from
infectionwithdormantformsoftheparasitewhichreactivate
later on, it is easier for the parasite to be transmitted in
a sustainable manner (Figure 2(a)). Latency then generates
a mechanism by which the parasite population can be
maintained in scenarios where vectors are not very abundant
or where human-mosquito contacts are sparse. Strikingly,
for any value of transmission coeﬃcient that sustains both
species, the proportion of individuals with a clinical episode
due to P. vivax is lower than that due to P. falciparum
(Figure 2(a)), while the overall parasite prevalence (mea-
sured as proportion of individuals in the population which
carry parasites in the blood stream and are thus potentially
infectious) is expected to be higher for P. vivax (Figure 2(c)).
Figures 2(b) and 2(d) display how equilibrium solutions
depend on the basic reproduction number, R0,a sap r o x yf o r
transmission.
Figure 3 simulates the introduction of malaria control
measures in an area supporting P. vivax transmission versus
in an area supporting P. falciparum transmission, with
the same parasite prevalence. The intervention consists of
applying an MDA (mass drug administration) campaign
using ACT aimed at reducing the infectious period of
asymptomatic infections, making all infections, regardless
of clinical outcome, last the same. Figure 3 portrays that
by treating asymptomatic infections equally for both species
one can reduce falciparum prevalence (red lines) to a much
greater extent than vivax prevalence (blue lines) within
the same time frame (dot-dashed lines). This intervention
alone leads to sustained elimination of P. falciparum if
implemented for 274 days (time for the system to enter
the basin on attraction of the disease-free equilibrium). In
the case of P. vivax, elimination is only possible through
a stochastic event, and even then the risk of reemergence
will be high as the disease-free equilibrium is unstable
for this system. If a drug that can eliminate the dormant
forms of the parasite (Primaquine) is included in the MDA
strategy, then the P. vivax dynamics approach those for P.
falciparum. However, once the intervention is halted the risk
for reemergence would still be much higher for P. vivax due
to instability of the disease-free equilibrium.
InFigure4,wesimulatetheageproﬁlesforP. vivax andP.
falciparum for an equal risk of infection (λ0). The predicted
age proﬁles for P. vivax (blue) display a higher value for
clinical malaria cases at the peak, when compared with P.
falciparum (red), and reveal a decrease in the average age
at infection. This means that the risk of a P. vivax episode
relative to the risk of having a P. falciparum episode is greater
in very young children and lower throughout childhood.
This is consistent in the two transmission settings chosen
for this illustration as well as for the entire transmission
spectrum.
4. Discussion
T h et r u ei m p a c to fP. vivax transmission on human popu-
lations stands in the shadow of the overwhelming mortality
and morbidity burden exerted by P. falciparum worldwide.
P. vivax importance has been increasingly recognized over
the years, and new estimates of the global malaria burden
revealedthatthereareslightlymorepeopleatriskofhavinga
P. vivax infectionthanaP.falciparuminfection[1].However,
probably more interesting is to consider the importance
and impact of P. vivax under the scope of its ecological
interactions with P. falciparum, especially considering that
coinfection with these species might somehow modulate
the clinical outcome of infection [21–23], and that there
might be cross-speciﬁc immunity [24–27]. Understanding
thetransmissiondynamicsofP. vivax iscrucialtounderstand
the current epidemiological scenario and the potential long-
term impact of control interventions.
We have previously developed a mathematical model
to represent the dynamics of P. falciparum transmissionJournal of Parasitology Research 5
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Figure 2: Expected clinical malaria episodes and parasite prevalence at equilibrium, for both P. vivax and P. falciparum. (a) Bifurcation
diagram, showing the inﬂuence of β on the equilibrium levels of clinical malaria for P. vivax (blue) and P. falciparum (red). (c) Inﬂuence of
β on the equilibrium levels of parasite prevalence (I1 + I2)f o rP. vivax (blue) and P. falciparum (red). (b) and (d) are similar to (a) and (c),
respectively, but use R0 as control parameter. For P. vivax,w eu s e dp1 = p2 = 0.25. Dashed lines represent unstable equilibrium solutions,
whilst full lines refer to stable endemic equilibria.
in human populations [13]. The model was calibrated on
hospitalization data from 8 endemic regions in sub-Saharan
Africa [28], estimating a fundamental diﬀerence between
the duration of clinical and asymptomatic infections. This
result led to the identiﬁcation of a deterministic elimination
threshold for P. falciparum malaria in areas of low to
moderate transmission. We adopted the same generic model
for P. vivax while adding latency classes to represent those
individuals who recover from infection with a remnant of
dormant parasites, called hypnozoites. These parasites can
reactivate at any given time causing a relapse.
Model outputs were generated and compared with and
without latent classes, to mimic vivax and falciparum,
respectively, while all other features were unchanged. The
expected levels of clinical episodes of both P. vivax and P.
falciparum for the same levels of the transmission coeﬃcient,
β, indicate that P. vivax transmission can be sustained
for much lower values of this parameter, when compared
with P. falciparum (Figure 2(a)). This becomes intuitive in
light of P. vivax’s ability to relapse, which can transform a
single infectious bite into more than one malaria episode
leading to higher parasite prevalence in the P. vivax system
(Figure 2(c)). These relationships are inverted, however,
when parasite prevalence is represented against the basic
reproduction number, R0, (Figures 2(b) and 2(d)) attesting
the importance of standardizing transmission indices. More
importantly, we have uncovered a qualitative change due to
the latency classes. The deterministic elimination threshold
described for the P. falciparum system is no longer present
under the conditions simulated for P. vivax. The parameter6 Journal of Parasitology Research
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Figure 3: Mass drug administration (MDA) strategy applied in
regions where P. falciparum (red) and P. vivax (blue) are equally
prevalent. The initial parasite prevalence is equal for both P. vivax
and P. falciparum as highlighted Figures 2(c) and 2(d) by V and
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and dashed lines display interventions with durations just below
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P. falciparum.F o rP. vivax, the model indicates no deterministic
elimination threshold. The blue solid line represents continuing the
intervention for 18 years and then halting, under p1 = p2 = 0.25.
The blue and red dot-dashed lines represent uninterrupted 20-year
MDA campaigns.
regime sustaining the bistability phenomenon that gives
rise to the elimination threshold is contracted when latency
comes into play.
A major advance in the search for eﬀective malaria
drug treatment, following the demise of most known
drugs in the battle against resistant parasites, came in
the form of artemisinin, a very potent and eﬀective
drugagainstchloroquineandsulphadoxine-pyrimethamine-
resistant infections, which can clear parasites and resolve
fever faster than any other licensed antimalarial [29].
However, artemisinin derivatives have a very short half-life,
translating into substantial treatment failures when used
as monotherapy [30], which motivated the combination
of artemisinin with longer-lasting partner drugs in the so-
called Artemisinin Combination Therapies (ACTs), assuring
that there is substantial antimalarial pressure to deal with
the residual parasite biomass that may persist when the
artemisinin derivatives have fallen below therapeutic levels
[31]. Curiously, empirical studies have revealed that the
deployment of ACT as a control strategy aﬀects P. falciparum
transmission much more than it does P. vivax transmission
[8, 9]. Furthermore, unexpected resurgences of P. vivax
malaria in areas where elimination attempts were thought to
have been successful question to what extent P. vivax control
is sustainable [32, 33]. Figure 3 supports these results in
emphatic fashion. Our simulations suggest that, by treating
all infections (equally for both species) with an ACT therapy,
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Figure 4: Age proﬁles for two transmission settings. Clinical P.
vivax malaria age proﬁles (blue lines) compared with P. falciparum
proﬁles (red lines) for equal risks of infection.
one can reduce falciparum prevalence to a much greater
extent than vivax prevalence (in the same time scale). This
is intrinsically associated with ACT’s inability to kill the
dormant forms of P. vivax, which escape drug action, subsist,
and can cause a relapse later on, thus sustaining the parasite
pool. In such scenario one should invoke the use of drugs
targeting hypnozoites (Primaquine is the only approved and
available drug at the moment) as a means of counteracting
the parasite’s ability to relapse. If everyone was to receive a
dose of Primaquine to kill the hypnozoite parasite forms,
the dynamics would be similar to that of P. falciparum.A
remaining diﬀerence, however, is that P. vivax elimination
is predicted to be unstable, meaning that any perturbation
in the system (introduction of infectious individuals from
neighboring populations for instance) would drive it back to
the endemic equilibrium.
Another epidemiological observation that deserves care-
ful consideration is the diﬀerential speed at which complete
clinical immunity is attained when comparing P. vivax to
P. falciparum for scenarios of equal risk of infection [9–
11]. While others have interpreted this phenomenon as
an evidence of there being diﬀerent mechanisms by which
immunity is acquired [12], our results suggest that the
diﬀerence in age proﬁles of clinical malaria can be accounted
for by the intrinsic transmission dynamics inherent to the
natural history of infection of each species. In Figure 4,
we can clearly see that the model topologies we used
to describe the P. vivax and P. falciparum transmission
dynamics can account for diﬀerences in the age proﬁles of
clinical malaria, speciﬁcally for low levels of p1 and p2.
We then propose that diﬀerences in age proﬁles of clinical
malaria can be explained solely by P. vivax’s ability to relapse,
which converts a single infectious mosquito bite into one
or more malaria infections, thus accelerating the acquisition
of clinical immunity. Relapse also serves as an immunityJournal of Parasitology Research 7
boostingmechanismthatpreventsonsetsofmalariaepisodes
in older ages.
On a ﬁnal note, we recall that all parameters other
than those governing hypnozoite formation and relapse
were unchanged between the two scenarios. P. vivax and
P. falciparum transmission dynamics might, however, be
modulated by a number of biological characteristics such
as gametocyte production and antigenic variation. Although
our model was not designed to explore these processes, some
analogies can be made as detailed in the Supplementary
Material available online at doi:10.1155/2012/921715. Two
aspectsareespeciallyurging.First,itshouldbeacknowledged
that P. vivax produces gametocytes earlier than P. falciparum
during a human infection and these gametocytes are shorter
lived in the bloodstream [34]. As a consequence, vivax
patients are expected to have transmitted more by the time
malaria infection is conﬁrmed and treatment is provided.
Second, the acquisition of immunity to P. vivax relies on
expectations regarding strain speciﬁcity of natural immunity
and antigenic similarity between primary infections and
relapses that deserve further attention [35, 36].
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